Claim: Sanofi to cut U.S. insulin costs for some patients to $99 per month.
Verdict: SUPPORTS

Retrieved passages:
title: Insulin (medication)
text: US$2.39 to $10.61 per 1,000 iu of regular insulin and $2.23 to $10.35 per 1,000 iu of NPH insulin. In the United Kingdom 1,000 iu of regular or NPH insulin costs the NHS £7.48, while this amount of insulin glargine costs £30.68. In the United States the unit price of insulin has increased steadily from 1991 to 2014. It rose threefold from 2002 to 2013. Costs can be as high as US$900 per month. Concerns were raised in 2016 of pharmaceutical companies working together to increase prices. In 2006 the U.S. Food and Drug Administration approved the use of Exubera,

title: Insulin glargine/lixisenatide
text: pharmacies in January 2017. Following FDA approval of Soliqua, Sanofi made a $25 million milestone payment to Zealand. Zealand may receive additional payments up to $110 million along with receiving royalties on global sales. Royalties paid to Zealand for Soliqua are based on a fixed low double-digit percentage of net sales. In January 2017, Sanofi announced that the wholesale acquisition cost (WAC) of a 3 ml pen of Soliqua is $127. At the average dose used in clinical trials, this amounts to $19.90 per day. According to Sanofi's Half-Year Financial Report, the net sales of Soliqua reached €9 million in

title: Insulin (medication)
text: system. The wholesale cost in the developing world is about US$2.39 to $10.61 per 1,000 iu (34.7 mg) of regular insulin and $2.23 to $10.35 per 1,000 iu of NPH insulin. In the United Kingdom 1,000 iu of regular or NPH insulin costs the NHS £7.48, while this amount of insulin glargine costs £30.68. Insulin is used to treat a number of diseases including diabetes and its acute complications such as diabetic ketoacidosis and hyperosmolar hyperglycemic states. It is also used along with glucose to treat high blood potassium levels. Insulin was formerly used in a psychiatric treatment called insulin

title: Minimed Paradigm
text: without increasing risk of hypoglycemia. The MiniMed Paradigm 522 and 722 Insulin Pumps have a list price of $6,195 while the optional starter kit for the CGM components list for US $999. Insurance coverage for the CGM system is possible under pharmacy benefits (vs. durable medical benefits which have typically a 20% co-pay). Approximately 30% of American patients with typical "commercial" coverage can process their CGM under pharmacy, while 90% of American patients are actually eligible for coverage if they meet plan requirements. The estimated out-of-pocket cost is US $0.86 per day for pharmacy benefit or US $2.33 per day

title: Regular insulin
text: developing world is about US$2.39–10.61 per 1,000 iu of regular insulin. In the United Kingdom 1,000 iu costs the NHS 7.48 pounds, while in the United States this amount is about $134.00. Versions are also available mixed with longer-acting versions of insulin, such as NPH insulin. It is used for the long-term management of diabetes. Regular insulin is the treatment of choice for the two diabetic emergencies diabetic ketoacidosis and hyperosmolar hyperglycemic states. It may also be used in combination with glucose to lower potassium levels in those with hyperkalemia. Side effects may include: low blood sugar levels, skin reactions

title: Insulin glargine/lixisenatide
text: around €3 billion in 2009. Sanofi planned to start the Phase III trial that year. Sanofi submitted the new drug application in December 2015 for the combination and spent a $245M priority voucher to gain a faster review, to try to outrace Novo Nordisk’s Xultophy, a similar combination drug of Novo's insulin Tresiba and Novo's GLP-1 agonist Victoza. Sanofi's application was considered by the same Endocrinologic and Metabolic Drugs Advisory FDA Committee that was considering lixisenatide as a single agent. In May 2016 by a vote of 12-2, with several members of the committee expressing reservations about Sanofi's plans to

title: Etanercept
text: cost of Enbrel was $1,500 per month or $18,000 per year. By 2011, the cost had exceeded $20,000 per year. In 2013, a survey by the International Federation of Health Plans (IFHP) found that the average U.S. cost for Enbrel was $2,225 per month, or $26,700 per year. The IFHP report also found wide variation in prices charged to various U.S. health plans, between $1,946 per month at the 25th percentile and $4,006 per month at the 95th percentile. Enbrel is more expensive in the U.S. than in other countries. As of 2013, average monthly costs in surveyed nations ranged

title: Inhalable insulin
text: trials to ensure that people would use it the same way as the earlier versions. After conducting further studies, Mannkind submitted a new application, and in June, 2014, the FDA approved Afrezza for both Type I and Type II adult diabetics, with a label restriction for patients having asthma, active lung cancer or COPD. In 2014 Mannkind and Sanofi agreed that Sanofi would take over manufacturing and marketing of Afrezza, but Sanofi said it was dropping the effort in January 2016 due to poor sales of $7.5 million in 2015; the companies formally terminated the agreement in November 2016. At

title: Artificial pancreas
text: to seven days. The device uses Bluetooth technology to warn the user either through a handheld receiver or app on a smartphone if blood glucose levels reach below a certain point. The cost for this device excluding any co-insurance is an estimated $4,800 a year. Abbott Laboratories' FreeStyle Libre CGM was approved in September 2017. It does not support smartphone use. This device does not require finger pricks at all and the sensor, placed on the upper arm, lasts 10 days. The estimated cost for this monitor is $1,300 a year. Dexcom's next G6 model CGM was approved in March

title: MannKind Corporation
text: Village, California. The Afrezza manufacturing facility is in Danbury, Connecticut. Afrezza is an rapid-acting insulin peaking 12 to 15 minutes after inhalation and exiting the body within 2–3 hours. The FDA approved Afrezza on June 27, 2014 with a 13-1 vote for type 1 diabetes and 14-0 vote for type 2 diabetes. On August 11, 2014 MannKind entered into an exclusive global licensing agreement with Sanofi for Afrezza sales. Under the agreement, MannKind received $150 million cash from Sanofi, in exchange for sharing profits and losses of sales of Afrezza, with 65% for Sanofi and 35% for MannKind. On January

title: Specialty drugs in the United States
text: Edward Island, Canada. The price increased from $40 a vial to $700 and continued to increase. By 2012 the price of a vial of Acthar was $28,400. and was considered to be one of the world's most expensive drugs in 2013. By 2014 the price of Gilead's specialty drug for hepatitis C, Sovaldi or "sofosbuvir", was $84,000 to $168,000 for a course of treatment in the U.S., £35,000 in the UK for 12 weeks. Sovaldi is on the World Health Organization's most important medications needed in a basic health system and the steep price is highly controversial. In 2014 the

title: Rosiglitazone
text: after the story first broke in 2007, dropping from $2.5 billion in 2006 to less than $408 million in 2009 in the US. In response to the rise in risk of heart attacks, the Indian government ordered GSK to suspend its research study, called TIDE, in 2010. The FDA also halted the TIDE study in the United States. Three doctors' groups, the Endocrine Society, the American Diabetes Association and the American Association of Clinical Endocrinologists, urged patients to continue to take the drug as it would be much worse to stop all treatment, despite any associated risk, but that patients

title: Insulin lispro
text: lipodystrophy. Other serious side effects include anaphylaxis, and hypersensitivity reactions. Do not administer insulin lispro during episodes of hypoglycemia, or if the patient has a hypersensitivity to insulin lispro or any of its excipients. In the United States, as of 2015, the cost is between $10.06 and $29.36 per 100 units. In Europe the price is far lower. The cost in the UK is between £1.66 (about $2.50) and £1.96 (about $3.00) per 100 units, as of 2017. Insulin lispro Insulin lispro, sold under the brand name Humalog among others, is a fast acting insulin analog. It was first approved

title: Gliclazide
text: on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is about US$2.46–3.92 per month. In the United Kingdom a month of medication costs the NHS about 2.12 pounds. It is not available for sale in the United States. Gliclazide is used for control of hyperglycemia in gliclazide-responsive diabetes mellitus of stable, mild, non-ketosis prone, type 2 diabetes. It is used when diabetes cannot be controlled by proper dietary management and exercise or when insulin therapy is not appropriate. National Kidney Foundation (2012

title: Hanmi Pharmaceutical
text: announcement on the 30th. In December three Hanmi employees were among 17 people indicted for insider trading; 25 people were fined, and 45 people were found to have made illegal trades that took around 3.3 billion won ($2.83 million) in profits based on the information. In December 2016 the Sanofi deal was reduced in scope, with Hanmi receiving back rights to the once-weekly insulin and the combination GLP1-RA/insulin product, and agreeing to repay Sanofi $250 million of the $434 million upfront payment. In April 2018 Hanmi was found to have violated two laws in Korea by not disclosing adverse effects

title: Prescription costs
text: price of over $400,000 per year per patient. The benefit of this drug is immense because it cures very rare diseases that would cost much more money to treat otherwise, which saves insurance companies and health agencies millions of dollars. Hence, insurance companies and health agencies are willing to pay these prices. Policy makers in some countries have placed controls on the amount pharmaceutical companies can raise the price of drugs. In 2017, Democratic party leaders proposed the creation of a new federal agency to investigate and perhaps fine drug manufacturers who make unjustified price increases. Pharmaceutical companies would be

title: Priority review
text: July 2014, Regeneron and Sanofi announced that they had purchased a priority review voucher that BioMarin had won for a recent rare disease drug approval for $67.5 million; the voucher cut four months off the regulatory review time for alirocumab and was part of their strategy to beat Amgen to market with the first approval of a PCSK9 inhibitor. In 2015, a voucher for a pediatric cancer drug developed by United Therapeutics sold for $350 million. At this cost, the voucher would be expected to offset the substantial investment and risk required for discovery and development of a new treatment

title: Sanofi
text: 2013. In 2007 Sanofi-Aventis expanded on Aventis' prior relationship with Regeneron; in the new deal Sanofi-Aventis agreed to pay Regeneron $100 million each year for five years, under which Regeneron would use its monoclonal antibody discovery platform to create new biopharmaceuticals, which Sanofi-Aventis gained the exclusive right to co-develop. In 2009 the companies expanded the deal to $160 million per year and extended it through 2017. As of 2009 the collaboration had four antibodies in clinical development and had filed an IND for a fifth. Two were against undisclosed targets, one targeted the interleukin-6 receptor as a treatment for rheumatoid

title: Sanofi
text: golden handshake he was getting from Sanofi - and his pay of about $4.7 million a year. Further, in 2014, the business took a 66% stake in Globalpharma, Dubai-based generics manufacturer. In July 2015, Genzyme announced it would acquire the rare cancer drug Caprelsa (vandetanib) from AstraZeneca for up to $300 million. In the same month In July 2015, the company announced a new global collaboration with Regeneron to discover, develop, and commercialise new immuno-oncology drugs, which could generate more than $2 billion for Regeneron, with $640 million upfront, $750 million for proof of concept data and $650 million from

title: Accredo
text: tolerance, Accredo gave only a half fill of prescription medications, then performed a clinical assessment to monitor patient drug tolerance and help ensure that patients do not take unnecessary or ineffective drugs. With the program, treatment options can also be reexamined if the drugs are working, but side effects are hindering quality of life. Accredo Accredo is a specialty pharmaceutical and service provider for patients with complex and chronic health conditions. Accredo provides specialty drugs, drugs that cost more than $600 per month, with the average being $10,000 a month, which treat serious conditions such as multiple sclerosis, rheumatoid arthritis,